Items where authors include "Brown, JE"

Article

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Gregory, W et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Zhong, J orcid.org/0000-0001-5325-3739, Palkhi, E, Buckley, DL orcid.org/0000-0001-6659-8365 et al. (7 more authors) (2021) Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics, 11 (7). 1302. ISSN 2075-4418

Tulotta, C, Lefley, DV, Freeman, K et al. (16 more authors) (2019) Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment. Clinical Cancer Research, 25 (9). pp. 2769-2782. ISSN 1078-0432

Westbrook, JA, Wood, SL, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2019) Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of pathology, 247 (3). pp. 381-391. ISSN 0022-3417

Coleman, RE, Collinson, M orcid.org/0000-0003-3568-6455, Gregory, W orcid.org/0000-0003-2641-8416 et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13. pp. 123-135. ISSN 2212-1374

Powles, T, Lackner, MR, Oudard, S et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 34 (14). pp. 1660-1668. ISSN 0732-183X

Westbrook, JA, Cairns, DA orcid.org/0000-0002-2338-0179, Peng, J et al. (10 more authors) (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. JNCI: Journal of the National Cancer Institute, 108 (4). ISSN 0027-8874

Rathbone, EJ, Brown, JE, Marshall, HC et al. (11 more authors) (2013) Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology, 31 (21). 2685 - 2691. ISSN 1527-7755

Conference or Workshop Item

Vasudev, NS orcid.org/0000-0001-8470-7481, Ainsworth, G, Brown, S orcid.org/0000-0002-7975-7537 et al. (17 more authors) (2021) LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). In: ESMO Congress 2021, 16-21 Sep 2021, Virtual.

Proceedings Paper

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Ralph, C et al. (17 more authors) (2021) STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). In: Annals of Oncology. ESMO Congress 2021, 16-21 Sep 2021, Paris, France. Elsevier , S1303-S1304.